CAB-2/MLN-2222 Development Service

Creative Biolabs’ technical experts have successfully established the proprietary complement therapeutics system. We are looking forward to designing a strategy to develop the preparation of CAB-2/MLN-2222 for our clients. Our customer service team of Ph.D. biologist can add real value to your research projects.

Complement System

The complement system is an evolutionarily well-conserved system of which the current complexity in jawed vertebrates emerged 600 million years ago, while some components of the most primitive complement system date 1.6 billion years back. Complement is a central element of innate immunity and this vital defense system initiates and coordinates immediate immune reactions which attack and eliminate microbes, foreign particles, and altered self-cells. Nowadays, three activation pathways of complement, initiated through distinct ligand-receptor interactions, are well-defined: the classical pathway, the lectin pathway, and the alternative pathway. The pathways converge at an amplification stage characterized by the formation of C3 and C5 convertases and cooperate closely to form opsonins, anaphylatoxins, chemoattractants, and membrane attack complexes (MACs).

CAB-2/MLN-2222 Development Service

CBA-2/MLN-2222

A number of promising approaches for the clinical substitution, inhibition or modulation of complement have been developed and are presented in the following section. Soluble forms of MCP, DAF, and CD59 have also been considered as therapeutics. Whereas DAF and MCP each offer only a single regulatory activity, a recombinant chimera of their extracellular parts has been developed. The resulting sDAF-sMCP hybrid was initially named “complement activity blocker 2” (CBA-2/MLN-2222, Millenium Pharmaceuticals).

Therefore, with its advanced biology technology, Creative Biolabs has mastered experience and expertise in protein and antibody expression, purification and so on. Our protein generation system can further support rapid and high-throughput protein production. Our CAB-2/MLN-2222 (Millenium Pharmaceuticals) Development Service can be tailor-designed to meet your specific needs and it is fast, reliable, and affordable. Our service including but not limited to:

  1. CAB-2/MLN-2222 (Millenium Pharmaceuticals) development
  2. Protein expression and purification
  3. Similar preparation development
  4. Other supports if clients need

What Do We Submit to You?

We will start the experiment immediately after receiving the raw materials and proof of payment you provided.

  1. The results obtained during the submission of the experiment include protein and plasmids (if you need).
  2. Lab Report: We will provide you with all the experimental results of each stage of the experiment in written and electronic form. Including the experimental data and analysis of each part: affinity determination results; sequencing and analysis of protein sequences.

If you are interested in using our CAB-2/MLN-2222 Development Service to support your clinical discovery and development program, please contact us for more details.

For Research Use Only.
Services

Online Inquiry